Viamet Pharmaceuticals Raises $4 Million Round of Financing

Drug Discovery and Development Company Focused on Metalloenzymes Closes Series A Round

Research Triangle Park , NC – Viamet Pharmaceuticals Inc., a biotechnology company targeting metalloenzymes in the fields of infectious disease, inflammation and oncology, announced today that it has closed a $4 million Series A financing round.

The financing was co-led by new investor Hatteras Venture Partners and founding investor Intersouth Partners, which previously provided seed funding for the company. Douglas Reed of Hatteras Venture Partners will join Garheng Kong of Intersouth Partners on the company’s Board of Directors.

“This Series A financing will support the rapid development of our metalloenzyme inhibitor programs,” said Robert Schotzinger, M.D., Ph.D., President and CEO of Viamet Pharmaceuticals. “We look forward to working with our financial partners as we continue to grow the company.”

“Having worked with Viamet since its founding, we’re very pleased to see the company reach this important milestone,” said Garheng Kong, M.D., Ph.D., of Intersouth Partners. “The technology is promising and there are significant market opportunities being pursued.”

“Viamet is an exciting investment opportunity,” said Douglas Reed, M.D., of Hatteras Venture Partners. “We believe the science creates new market opportunities and we look forward to working with Viamet to develop these interesting and important compounds.”